IL
Illinois Senate Bill SB3437

Illinois 2023-2024 Regular Session

Illinois Senate Bill SB3437 Compare Versions

Only one version of the bill is available at this time.
OldNewDifferences
11 103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 SB3437 Introduced 2/8/2024, by Sen. David Koehler SYNOPSIS AS INTRODUCED: 720 ILCS 570/316.1720 ILCS 570/318 Amends the Illinois Controlled Substances Act. Deletes provision that any entity or system for integration (transmitting the data maintained by the Prescription Monitoring Program) into an Electronic Health Records System, Certified Health IT Module, Pharmacy Dispensing System, or Pharmacy Management System must meet applicable requirements outlined in administrative rules of the Department of Human Services. Provides that any entity or system for integration (transmitting the data maintained by the Prescription Monitoring Program) into an Electronic Health Records System, Certified Health IT Module, Pharmacy Dispensing System, or Pharmacy Management System that meets either the requirements of at least one certification criterion adopted under the Office of National Coordinator for Health Information Technology (ONC) or HITRUST certification shall be deemed qualified by the Department of Human Services to integrate pharmacy records with the Prescription Monitoring Program, subject to specified requirements. Defines "one-to-one secure link". LRB103 38535 RLC 68671 b A BILL FOR 103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 SB3437 Introduced 2/8/2024, by Sen. David Koehler SYNOPSIS AS INTRODUCED: 720 ILCS 570/316.1720 ILCS 570/318 720 ILCS 570/316.1 720 ILCS 570/318 Amends the Illinois Controlled Substances Act. Deletes provision that any entity or system for integration (transmitting the data maintained by the Prescription Monitoring Program) into an Electronic Health Records System, Certified Health IT Module, Pharmacy Dispensing System, or Pharmacy Management System must meet applicable requirements outlined in administrative rules of the Department of Human Services. Provides that any entity or system for integration (transmitting the data maintained by the Prescription Monitoring Program) into an Electronic Health Records System, Certified Health IT Module, Pharmacy Dispensing System, or Pharmacy Management System that meets either the requirements of at least one certification criterion adopted under the Office of National Coordinator for Health Information Technology (ONC) or HITRUST certification shall be deemed qualified by the Department of Human Services to integrate pharmacy records with the Prescription Monitoring Program, subject to specified requirements. Defines "one-to-one secure link". LRB103 38535 RLC 68671 b LRB103 38535 RLC 68671 b A BILL FOR
22 103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 SB3437 Introduced 2/8/2024, by Sen. David Koehler SYNOPSIS AS INTRODUCED:
33 720 ILCS 570/316.1720 ILCS 570/318 720 ILCS 570/316.1 720 ILCS 570/318
44 720 ILCS 570/316.1
55 720 ILCS 570/318
66 Amends the Illinois Controlled Substances Act. Deletes provision that any entity or system for integration (transmitting the data maintained by the Prescription Monitoring Program) into an Electronic Health Records System, Certified Health IT Module, Pharmacy Dispensing System, or Pharmacy Management System must meet applicable requirements outlined in administrative rules of the Department of Human Services. Provides that any entity or system for integration (transmitting the data maintained by the Prescription Monitoring Program) into an Electronic Health Records System, Certified Health IT Module, Pharmacy Dispensing System, or Pharmacy Management System that meets either the requirements of at least one certification criterion adopted under the Office of National Coordinator for Health Information Technology (ONC) or HITRUST certification shall be deemed qualified by the Department of Human Services to integrate pharmacy records with the Prescription Monitoring Program, subject to specified requirements. Defines "one-to-one secure link".
77 LRB103 38535 RLC 68671 b LRB103 38535 RLC 68671 b
88 LRB103 38535 RLC 68671 b
99 A BILL FOR
1010 SB3437LRB103 38535 RLC 68671 b SB3437 LRB103 38535 RLC 68671 b
1111 SB3437 LRB103 38535 RLC 68671 b
1212 1 AN ACT concerning criminal law.
1313 2 Be it enacted by the People of the State of Illinois,
1414 3 represented in the General Assembly:
1515 4 Section 5. The Illinois Controlled Substances Act is
1616 5 amended by changing Sections 316.1 and 318 as follows:
1717 6 (720 ILCS 570/316.1)
1818 7 (This Section may contain text from a Public Act with a
1919 8 delayed effective date)
2020 9 Sec. 316.1. Access to the integration of pharmacy records
2121 10 with the Prescription Monitoring Program.
2222 11 (a) Subject to the requirements and limitations set out in
2323 12 this Section and in administrative rule, the Department shall
2424 13 not require, either expressly or effectively, Electronic
2525 14 Health Records Systems, pharmacies, or other providers to
2626 15 utilize a particular entity or system for access to the
2727 16 integration of pharmacy records with the Prescription
2828 17 Monitoring Program.
2929 18 (1) Any entity or system for integration (transmitting
3030 19 the data maintained by the Prescription Monitoring
3131 20 Program) into an Electronic Health Records System,
3232 21 Certified Health IT Module, Pharmacy Dispensing System, or
3333 22 Pharmacy Management System that meets either the
3434 23 requirements of at least one certification criterion
3535
3636
3737
3838 103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 SB3437 Introduced 2/8/2024, by Sen. David Koehler SYNOPSIS AS INTRODUCED:
3939 720 ILCS 570/316.1720 ILCS 570/318 720 ILCS 570/316.1 720 ILCS 570/318
4040 720 ILCS 570/316.1
4141 720 ILCS 570/318
4242 Amends the Illinois Controlled Substances Act. Deletes provision that any entity or system for integration (transmitting the data maintained by the Prescription Monitoring Program) into an Electronic Health Records System, Certified Health IT Module, Pharmacy Dispensing System, or Pharmacy Management System must meet applicable requirements outlined in administrative rules of the Department of Human Services. Provides that any entity or system for integration (transmitting the data maintained by the Prescription Monitoring Program) into an Electronic Health Records System, Certified Health IT Module, Pharmacy Dispensing System, or Pharmacy Management System that meets either the requirements of at least one certification criterion adopted under the Office of National Coordinator for Health Information Technology (ONC) or HITRUST certification shall be deemed qualified by the Department of Human Services to integrate pharmacy records with the Prescription Monitoring Program, subject to specified requirements. Defines "one-to-one secure link".
4343 LRB103 38535 RLC 68671 b LRB103 38535 RLC 68671 b
4444 LRB103 38535 RLC 68671 b
4545 A BILL FOR
4646
4747
4848
4949
5050
5151 720 ILCS 570/316.1
5252 720 ILCS 570/318
5353
5454
5555
5656 LRB103 38535 RLC 68671 b
5757
5858
5959
6060
6161
6262
6363
6464
6565
6666 SB3437 LRB103 38535 RLC 68671 b
6767
6868
6969 SB3437- 2 -LRB103 38535 RLC 68671 b SB3437 - 2 - LRB103 38535 RLC 68671 b
7070 SB3437 - 2 - LRB103 38535 RLC 68671 b
7171 1 adopted under the Office of National Coordinator for
7272 2 Health Information Technology (ONC) or HITRUST
7373 3 certification shall be deemed qualified by the Department
7474 4 to integrate pharmacy records with the Prescription
7575 5 Monitoring Program, subject to must meet applicable
7676 6 requirements outlined in administrative rule, including,
7777 7 but not limited to, the following:
7878 8 (A) enter into a data sharing agreement with the
7979 9 Department of Human Services, Prescription Monitoring
8080 10 Program;
8181 11 (B) all security requirements noted within this
8282 12 Section, administrative rule, and all other applicable
8383 13 State and federal security and privacy requirements;
8484 14 (C) the Prescription Monitoring Program shall have
8585 15 administrative control over the approval of each site
8686 16 and individual integration point and the Prescription
8787 17 Monitoring Program shall have the ability to disable
8888 18 individual integration points, at no additional cost
8989 19 to the State;
9090 20 (D) interstate data sharing shall be completed
9191 21 with written authorization from the Prescription
9292 22 Monitoring Program;
9393 23 (E) data available from the Prescription
9494 24 Monitoring Program shall not be stored, cached, or
9595 25 sold and the State may inspect and review an entity or
9696 26 system for integration to assure and confirm the same,
9797
9898
9999
100100
101101
102102 SB3437 - 2 - LRB103 38535 RLC 68671 b
103103
104104
105105 SB3437- 3 -LRB103 38535 RLC 68671 b SB3437 - 3 - LRB103 38535 RLC 68671 b
106106 SB3437 - 3 - LRB103 38535 RLC 68671 b
107107 1 subject to a reasonable non-disclosure agreement, as
108108 2 permitted by State law, to protect the entity's or
109109 3 system's trade secrets or other proprietary
110110 4 information;
111111 5 (F) analysis of data shall only be allowed with
112112 6 express written permission from the Prescription
113113 7 Monitoring Program; and
114114 8 (G) access to audit data, shall be available in
115115 9 hourly to real-time increments at no cost to the
116116 10 State.
117117 11 (2) Electronic Health Record Systems, Certified Health
118118 12 IT Modules, Pharmacy Management Systems, and Pharmacy
119119 13 Dispensing Systems integrated with the Prescription
120120 14 Monitoring Program must meet applicable requirements
121121 15 outlined in rule, including, but not limited to, the
122122 16 following:
123123 17 (A) provide their customers (healthcare entity,
124124 18 pharmacy, provider, prescriber, dispenser, etc.) the
125125 19 choice of approved integration vendor, meeting the
126126 20 requirements of this Section and administrative rule,
127127 21 or direct connect to the Illinois Prescription
128128 22 Monitoring Program;
129129 23 (B) provide their customers with access to the
130130 24 data provided by the customer's chosen integration
131131 25 vendor as allowed under State and federal statute; and
132132 26 (C) follow all State and federal security and
133133
134134
135135
136136
137137
138138 SB3437 - 3 - LRB103 38535 RLC 68671 b
139139
140140
141141 SB3437- 4 -LRB103 38535 RLC 68671 b SB3437 - 4 - LRB103 38535 RLC 68671 b
142142 SB3437 - 4 - LRB103 38535 RLC 68671 b
143143 1 privacy standards.
144144 2 (3) Customers required to integrate under State or
145145 3 federal law must meet the requirements outlined in
146146 4 administrative rule, including, but not limited to, the
147147 5 following:
148148 6 (A) the customer retains the choice of which
149149 7 integration vendor or direct connect is utilized to
150150 8 connect to the Illinois Prescription Monitoring
151151 9 Program; and
152152 10 (B) customers seeking to contract with a new
153153 11 integration vendor, shall enter into a memorandum of
154154 12 understanding with the Prescription Monitoring
155155 13 Program.
156156 14 (b) The Illinois Prescription Monitoring Program may
157157 15 exercise the power, by rule, to require Memoranda of
158158 16 Understanding with all customers. The general contents of the
159159 17 memorandum of understanding shall be set out in rule and shall
160160 18 include, but not be limited to:
161161 19 (1) the acknowledgment and choice of the customer of
162162 20 the method of integration with the Prescription Monitoring
163163 21 Program and
164164 22 (2) the data use and other requirements on the
165165 23 customer in accessing and using the Prescription
166166 24 Monitoring Program.
167167 25 A fee cannot be levied as part of a memorandum of
168168 26 understanding required by the Department under this Section.
169169
170170
171171
172172
173173
174174 SB3437 - 4 - LRB103 38535 RLC 68671 b
175175
176176
177177 SB3437- 5 -LRB103 38535 RLC 68671 b SB3437 - 5 - LRB103 38535 RLC 68671 b
178178 SB3437 - 5 - LRB103 38535 RLC 68671 b
179179 1 (c) Non-compliance by the Integration Vendor, Electronic
180180 2 Health Record System, Certified Health IT Module, Pharmacy
181181 3 Management System or Pharmacy Dispensing System, customer, or
182182 4 any parties required to comply with this Section may result in
183183 5 the party being prohibited from serving as entity or system
184184 6 for integration with the Prescription Monitoring Program,
185185 7 termination of contracts, agreements, or other business
186186 8 relationships. The Department shall institute appropriate cure
187187 9 notices, as necessary to remedy non-compliance.
188188 10 (Source: P.A. 103-477, eff. 7-1-24.)
189189 11 (720 ILCS 570/318)
190190 12 Sec. 318. Confidentiality of information.
191191 13 (a) Information received by the central repository under
192192 14 Section 316 and former Section 321 is confidential.
193193 15 (a-1) To ensure the federal Health Insurance Portability
194194 16 and Accountability Act and confidentiality of substance use
195195 17 disorder patient records rules that mandate the privacy of an
196196 18 individual's prescription data reported to the Prescription
197197 19 Monitoring Program received from a retail dispenser under this
198198 20 Act, and in order to execute the duties and responsibilities
199199 21 under Section 316 of this Act and rules for disclosure under
200200 22 this Section, the Clinical Director of the Prescription
201201 23 Monitoring Program or his or her designee shall maintain
202202 24 direct access to all Prescription Monitoring Program data. Any
203203 25 request for Prescription Monitoring Program data from any
204204
205205
206206
207207
208208
209209 SB3437 - 5 - LRB103 38535 RLC 68671 b
210210
211211
212212 SB3437- 6 -LRB103 38535 RLC 68671 b SB3437 - 6 - LRB103 38535 RLC 68671 b
213213 SB3437 - 6 - LRB103 38535 RLC 68671 b
214214 1 other department or agency must be approved in writing by the
215215 2 Clinical Director of the Prescription Monitoring Program or
216216 3 his or her designee unless otherwise permitted by law.
217217 4 Prescription Monitoring Program data shall only be disclosed
218218 5 as permitted by law.
219219 6 (a-2) As an active step to address the current opioid
220220 7 crisis in this State and to prevent and reduce addiction
221221 8 resulting from a sports injury or an accident, the
222222 9 Prescription Monitoring Program and the Department of Public
223223 10 Health shall coordinate a continuous review of the
224224 11 Prescription Monitoring Program and the Department of Public
225225 12 Health data to determine if a patient may be at risk of opioid
226226 13 addiction. Each patient discharged from any medical facility
227227 14 with an International Classification of Disease, 10th edition
228228 15 code related to a sport or accident injury shall be subject to
229229 16 the data review. If the discharged patient is dispensed a
230230 17 controlled substance, the Prescription Monitoring Program
231231 18 shall alert the patient's prescriber as to the addiction risk
232232 19 and urge each to follow the Centers for Disease Control and
233233 20 Prevention guidelines or his or her respective profession's
234234 21 treatment guidelines related to the patient's injury. This
235235 22 subsection (a-2), other than this sentence, is inoperative on
236236 23 or after January 1, 2024.
237237 24 (b) The Department must carry out a program to protect the
238238 25 confidentiality of the information described in subsection
239239 26 (a). The Department may disclose the information to another
240240
241241
242242
243243
244244
245245 SB3437 - 6 - LRB103 38535 RLC 68671 b
246246
247247
248248 SB3437- 7 -LRB103 38535 RLC 68671 b SB3437 - 7 - LRB103 38535 RLC 68671 b
249249 SB3437 - 7 - LRB103 38535 RLC 68671 b
250250 1 person only under subsection (c), (d), or (f) and may charge a
251251 2 fee not to exceed the actual cost of furnishing the
252252 3 information.
253253 4 (c) The Department may disclose confidential information
254254 5 described in subsection (a) to any person who is engaged in
255255 6 receiving, processing, or storing the information.
256256 7 (d) The Department may release confidential information
257257 8 described in subsection (a) to the following persons:
258258 9 (1) A governing body that licenses practitioners and
259259 10 is engaged in an investigation, an adjudication, or a
260260 11 prosecution of a violation under any State or federal law
261261 12 that involves a controlled substance.
262262 13 (2) An investigator for the Consumer Protection
263263 14 Division of the office of the Attorney General, a
264264 15 prosecuting attorney, the Attorney General, a deputy
265265 16 Attorney General, or an investigator from the office of
266266 17 the Attorney General, who is engaged in any of the
267267 18 following activities involving controlled substances:
268268 19 (A) an investigation;
269269 20 (B) an adjudication; or
270270 21 (C) a prosecution of a violation under any State
271271 22 or federal law that involves a controlled substance.
272272 23 (3) A law enforcement officer who is:
273273 24 (A) authorized by the Illinois State Police or the
274274 25 office of a county sheriff or State's Attorney or
275275 26 municipal police department of Illinois to receive
276276
277277
278278
279279
280280
281281 SB3437 - 7 - LRB103 38535 RLC 68671 b
282282
283283
284284 SB3437- 8 -LRB103 38535 RLC 68671 b SB3437 - 8 - LRB103 38535 RLC 68671 b
285285 SB3437 - 8 - LRB103 38535 RLC 68671 b
286286 1 information of the type requested for the purpose of
287287 2 investigations involving controlled substances; or
288288 3 (B) approved by the Department to receive
289289 4 information of the type requested for the purpose of
290290 5 investigations involving controlled substances; and
291291 6 (C) engaged in the investigation or prosecution of
292292 7 a violation under any State or federal law that
293293 8 involves a controlled substance.
294294 9 (4) Select representatives of the Department of
295295 10 Children and Family Services through the indirect online
296296 11 request process. Access shall be established by an
297297 12 intergovernmental agreement between the Department of
298298 13 Children and Family Services and the Department of Human
299299 14 Services.
300300 15 (e) Before the Department releases confidential
301301 16 information under subsection (d), the applicant must
302302 17 demonstrate in writing to the Department that:
303303 18 (1) the applicant has reason to believe that a
304304 19 violation under any State or federal law that involves a
305305 20 controlled substance has occurred; and
306306 21 (2) the requested information is reasonably related to
307307 22 the investigation, adjudication, or prosecution of the
308308 23 violation described in subdivision (1).
309309 24 (f) The Department may receive and release prescription
310310 25 record information under Section 316 and former Section 321
311311 26 to:
312312
313313
314314
315315
316316
317317 SB3437 - 8 - LRB103 38535 RLC 68671 b
318318
319319
320320 SB3437- 9 -LRB103 38535 RLC 68671 b SB3437 - 9 - LRB103 38535 RLC 68671 b
321321 SB3437 - 9 - LRB103 38535 RLC 68671 b
322322 1 (1) a governing body that licenses practitioners;
323323 2 (2) an investigator for the Consumer Protection
324324 3 Division of the office of the Attorney General, a
325325 4 prosecuting attorney, the Attorney General, a deputy
326326 5 Attorney General, or an investigator from the office of
327327 6 the Attorney General;
328328 7 (3) any Illinois law enforcement officer who is:
329329 8 (A) authorized to receive the type of information
330330 9 released; and
331331 10 (B) approved by the Department to receive the type
332332 11 of information released; or
333333 12 (4) prescription monitoring entities in other states
334334 13 per the provisions outlined in subsection (g) and (h)
335335 14 below;
336336 15 confidential prescription record information collected under
337337 16 Sections 316 and 321 (now repealed) that identifies vendors or
338338 17 practitioners, or both, who are prescribing or dispensing
339339 18 large quantities of Schedule II, III, IV, or V controlled
340340 19 substances outside the scope of their practice, pharmacy, or
341341 20 business, as determined by the Advisory Committee created by
342342 21 Section 320.
343343 22 (f-5) In accordance with a confidentiality agreement
344344 23 entered into with the Department, a medical director, or a
345345 24 public health administrator and their delegated analysts, of a
346346 25 county or municipal health department or the Department of
347347 26 Public Health shall have access to data from the system for any
348348
349349
350350
351351
352352
353353 SB3437 - 9 - LRB103 38535 RLC 68671 b
354354
355355
356356 SB3437- 10 -LRB103 38535 RLC 68671 b SB3437 - 10 - LRB103 38535 RLC 68671 b
357357 SB3437 - 10 - LRB103 38535 RLC 68671 b
358358 1 of the following purposes:
359359 2 (1) developing education programs or public health
360360 3 interventions relating to prescribing trends and
361361 4 controlled substance use; or
362362 5 (2) conducting analyses and publish reports on
363363 6 prescribing trends in their respective jurisdictions.
364364 7 At a minimum, the confidentiality agreement entered into
365365 8 with the Department shall:
366366 9 (i) prohibit analysis and reports produced under
367367 10 subparagraph (2) from including information that
368368 11 identifies, by name, license, or address, any
369369 12 practitioner, dispenser, ultimate user, or other person
370370 13 administering a controlled substance; and
371371 14 (ii) specify the appropriate technical and physical
372372 15 safeguards that the county or municipal health department
373373 16 must implement to ensure the privacy and security of data
374374 17 obtained from the system. The data from the system shall
375375 18 not be admissible as evidence, nor discoverable in any
376376 19 action of any kind in any court or before any tribunal,
377377 20 board, agency, or person. The disclosure of any such
378378 21 information or data, whether proper or improper, shall not
379379 22 waive or have any effect upon its confidentiality,
380380 23 non-discoverability, or non-admissibility.
381381 24 (g) The information described in subsection (f) may not be
382382 25 released until it has been reviewed by an employee of the
383383 26 Department who is licensed as a prescriber or a dispenser and
384384
385385
386386
387387
388388
389389 SB3437 - 10 - LRB103 38535 RLC 68671 b
390390
391391
392392 SB3437- 11 -LRB103 38535 RLC 68671 b SB3437 - 11 - LRB103 38535 RLC 68671 b
393393 SB3437 - 11 - LRB103 38535 RLC 68671 b
394394 1 until that employee has certified that further investigation
395395 2 is warranted. However, failure to comply with this subsection
396396 3 (g) does not invalidate the use of any evidence that is
397397 4 otherwise admissible in a proceeding described in subsection
398398 5 (h).
399399 6 (h) An investigator or a law enforcement officer receiving
400400 7 confidential information under subsection (c), (d), or (f) may
401401 8 disclose the information to a law enforcement officer or an
402402 9 attorney for the office of the Attorney General for use as
403403 10 evidence in the following:
404404 11 (1) A proceeding under any State or federal law that
405405 12 involves a controlled substance.
406406 13 (2) A criminal proceeding or a proceeding in juvenile
407407 14 court that involves a controlled substance.
408408 15 (i) The Department may compile statistical reports from
409409 16 the information described in subsection (a). The reports must
410410 17 not include information that identifies, by name, license or
411411 18 address, any practitioner, dispenser, ultimate user, or other
412412 19 person administering a controlled substance.
413413 20 (j) Based upon federal, initial and maintenance funding, a
414414 21 prescriber and dispenser inquiry system shall be developed to
415415 22 assist the health care community in its goal of effective
416416 23 clinical practice and to prevent patients from diverting or
417417 24 abusing medications.
418418 25 (1) An inquirer shall have read-only access to a
419419 26 stand-alone database which shall contain records for the
420420
421421
422422
423423
424424
425425 SB3437 - 11 - LRB103 38535 RLC 68671 b
426426
427427
428428 SB3437- 12 -LRB103 38535 RLC 68671 b SB3437 - 12 - LRB103 38535 RLC 68671 b
429429 SB3437 - 12 - LRB103 38535 RLC 68671 b
430430 1 previous 12 months.
431431 2 (2) Dispensers may, upon positive and secure
432432 3 identification, make an inquiry on a patient or customer
433433 4 solely for a medical purpose as delineated within the
434434 5 federal HIPAA law.
435435 6 (3) The Department shall provide a one-to-one secure
436436 7 link and encrypted software necessary to establish the
437437 8 link between an inquirer and the Department. Technical
438438 9 assistance shall also be provided. "One-to-one secure
439439 10 link" only means connecting a provider and the Illinois
440440 11 Prescription Monitoring Program through an electronic
441441 12 health record or a pharmacy management system by issuing
442442 13 unique credentials for each connecting system that can be
443443 14 individually approved or denied by the Illinois
444444 15 Prescription Monitoring Program. "One-to-one secure link"
445445 16 refers only to the access controls and approval of
446446 17 credentials, not the routing path of the transaction.
447447 18 "One-to-one secure link" or "one-to-one connection" does
448448 19 not mean that the integrating service will provide a
449449 20 direct connection between the Electronic health Records
450450 21 System or pharmacy management system and the Illinois
451451 22 Prescription Monitoring Program.
452452 23 (4) Written inquiries are acceptable but must include
453453 24 the fee and the requester's Drug Enforcement
454454 25 Administration license number and submitted upon the
455455 26 requester's business stationery.
456456
457457
458458
459459
460460
461461 SB3437 - 12 - LRB103 38535 RLC 68671 b
462462
463463
464464 SB3437- 13 -LRB103 38535 RLC 68671 b SB3437 - 13 - LRB103 38535 RLC 68671 b
465465 SB3437 - 13 - LRB103 38535 RLC 68671 b
466466 1 (5) As directed by the Prescription Monitoring Program
467467 2 Advisory Committee and the Clinical Director for the
468468 3 Prescription Monitoring Program, aggregate data that does
469469 4 not indicate any prescriber, practitioner, dispenser, or
470470 5 patient may be used for clinical studies.
471471 6 (6) Tracking analysis shall be established and used
472472 7 per administrative rule.
473473 8 (7) Nothing in this Act or Illinois law shall be
474474 9 construed to require a prescriber or dispenser to make use
475475 10 of this inquiry system.
476476 11 (8) If there is an adverse outcome because of a
477477 12 prescriber or dispenser making an inquiry, which is
478478 13 initiated in good faith, the prescriber or dispenser shall
479479 14 be held harmless from any civil liability.
480480 15 (k) The Department shall establish, by rule, the process
481481 16 by which to evaluate possible erroneous association of
482482 17 prescriptions to any licensed prescriber or end user of the
483483 18 Illinois Prescription Information Library (PIL).
484484 19 (l) The Prescription Monitoring Program Advisory Committee
485485 20 is authorized to evaluate the need for and method of
486486 21 establishing a patient specific identifier.
487487 22 (m) Patients who identify prescriptions attributed to them
488488 23 that were not obtained by them shall be given access to their
489489 24 personal prescription history pursuant to the validation
490490 25 process as set forth by administrative rule.
491491 26 (n) The Prescription Monitoring Program is authorized to
492492
493493
494494
495495
496496
497497 SB3437 - 13 - LRB103 38535 RLC 68671 b
498498
499499
500500 SB3437- 14 -LRB103 38535 RLC 68671 b SB3437 - 14 - LRB103 38535 RLC 68671 b
501501 SB3437 - 14 - LRB103 38535 RLC 68671 b
502502 1 develop operational push reports to entities with compatible
503503 2 electronic medical records. The process shall be covered
504504 3 within administrative rule established by the Department.
505505 4 (o) Hospital emergency departments and freestanding
506506 5 healthcare facilities providing healthcare to walk-in patients
507507 6 may obtain, for the purpose of improving patient care, a
508508 7 unique identifier for each shift to utilize the PIL system.
509509 8 (p) The Prescription Monitoring Program shall
510510 9 automatically create a log-in to the inquiry system when a
511511 10 prescriber or dispenser obtains or renews his or her
512512 11 controlled substance license. The Department of Financial and
513513 12 Professional Regulation must provide the Prescription
514514 13 Monitoring Program with electronic access to the license
515515 14 information of a prescriber or dispenser to facilitate the
516516 15 creation of this profile. The Prescription Monitoring Program
517517 16 shall send the prescriber or dispenser information regarding
518518 17 the inquiry system, including instructions on how to log into
519519 18 the system, instructions on how to use the system to promote
520520 19 effective clinical practice, and opportunities for continuing
521521 20 education for the prescribing of controlled substances. The
522522 21 Prescription Monitoring Program shall also send to all
523523 22 enrolled prescribers, dispensers, and designees information
524524 23 regarding the unsolicited reports produced pursuant to Section
525525 24 314.5 of this Act.
526526 25 (q) A prescriber or dispenser may authorize a designee to
527527 26 consult the inquiry system established by the Department under
528528
529529
530530
531531
532532
533533 SB3437 - 14 - LRB103 38535 RLC 68671 b
534534
535535
536536 SB3437- 15 -LRB103 38535 RLC 68671 b SB3437 - 15 - LRB103 38535 RLC 68671 b
537537 SB3437 - 15 - LRB103 38535 RLC 68671 b
538538 1 this subsection on his or her behalf, provided that all the
539539 2 following conditions are met:
540540 3 (1) the designee so authorized is employed by the same
541541 4 hospital or health care system; is employed by the same
542542 5 professional practice; or is under contract with such
543543 6 practice, hospital, or health care system;
544544 7 (2) the prescriber or dispenser takes reasonable steps
545545 8 to ensure that such designee is sufficiently competent in
546546 9 the use of the inquiry system;
547547 10 (3) the prescriber or dispenser remains responsible
548548 11 for ensuring that access to the inquiry system by the
549549 12 designee is limited to authorized purposes and occurs in a
550550 13 manner that protects the confidentiality of the
551551 14 information obtained from the inquiry system, and remains
552552 15 responsible for any breach of confidentiality; and
553553 16 (4) the ultimate decision as to whether or not to
554554 17 prescribe or dispense a controlled substance remains with
555555 18 the prescriber or dispenser.
556556 19 The Prescription Monitoring Program shall send to
557557 20 registered designees information regarding the inquiry system,
558558 21 including instructions on how to log onto the system.
559559 22 (r) The Prescription Monitoring Program shall maintain an
560560 23 Internet website in conjunction with its prescriber and
561561 24 dispenser inquiry system. This website shall include, at a
562562 25 minimum, the following information:
563563 26 (1) current clinical guidelines developed by health
564564
565565
566566
567567
568568
569569 SB3437 - 15 - LRB103 38535 RLC 68671 b
570570
571571
572572 SB3437- 16 -LRB103 38535 RLC 68671 b SB3437 - 16 - LRB103 38535 RLC 68671 b
573573 SB3437 - 16 - LRB103 38535 RLC 68671 b
574574 1 care professional organizations on the prescribing of
575575 2 opioids or other controlled substances as determined by
576576 3 the Advisory Committee;
577577 4 (2) accredited continuing education programs related
578578 5 to prescribing of controlled substances;
579579 6 (3) programs or information developed by health care
580580 7 professionals that may be used to assess patients or help
581581 8 ensure compliance with prescriptions;
582582 9 (4) updates from the Food and Drug Administration, the
583583 10 Centers for Disease Control and Prevention, and other
584584 11 public and private organizations which are relevant to
585585 12 prescribing;
586586 13 (5) relevant medical studies related to prescribing;
587587 14 (6) other information regarding the prescription of
588588 15 controlled substances; and
589589 16 (7) information regarding prescription drug disposal
590590 17 events, including take-back programs or other disposal
591591 18 options or events.
592592 19 The content of the Internet website shall be periodically
593593 20 reviewed by the Prescription Monitoring Program Advisory
594594 21 Committee as set forth in Section 320 and updated in
595595 22 accordance with the recommendation of the advisory committee.
596596 23 (s) The Prescription Monitoring Program shall regularly
597597 24 send electronic updates to the registered users of the
598598 25 Program. The Prescription Monitoring Program Advisory
599599 26 Committee shall review any communications sent to registered
600600
601601
602602
603603
604604
605605 SB3437 - 16 - LRB103 38535 RLC 68671 b
606606
607607
608608 SB3437- 17 -LRB103 38535 RLC 68671 b SB3437 - 17 - LRB103 38535 RLC 68671 b
609609 SB3437 - 17 - LRB103 38535 RLC 68671 b
610610 1 users and also make recommendations for communications as set
611611 2 forth in Section 320. These updates shall include the
612612 3 following information:
613613 4 (1) opportunities for accredited continuing education
614614 5 programs related to prescribing of controlled substances;
615615 6 (2) current clinical guidelines developed by health
616616 7 care professional organizations on the prescribing of
617617 8 opioids or other drugs as determined by the Advisory
618618 9 Committee;
619619 10 (3) programs or information developed by health care
620620 11 professionals that may be used to assess patients or help
621621 12 ensure compliance with prescriptions;
622622 13 (4) updates from the Food and Drug Administration, the
623623 14 Centers for Disease Control and Prevention, and other
624624 15 public and private organizations which are relevant to
625625 16 prescribing;
626626 17 (5) relevant medical studies related to prescribing;
627627 18 (6) other information regarding prescribing of
628628 19 controlled substances;
629629 20 (7) information regarding prescription drug disposal
630630 21 events, including take-back programs or other disposal
631631 22 options or events; and
632632 23 (8) reminders that the Prescription Monitoring Program
633633 24 is a useful clinical tool.
634634 25 (t) Notwithstanding any other provision of this Act,
635635 26 neither the Prescription Monitoring Program nor any other
636636
637637
638638
639639
640640
641641 SB3437 - 17 - LRB103 38535 RLC 68671 b
642642
643643
644644 SB3437- 18 -LRB103 38535 RLC 68671 b SB3437 - 18 - LRB103 38535 RLC 68671 b
645645 SB3437 - 18 - LRB103 38535 RLC 68671 b
646646
647647
648648
649649
650650
651651 SB3437 - 18 - LRB103 38535 RLC 68671 b